Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pcreb and cd39

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zhong, Shi Ying ^a   Chen, Yong Xing ^a   Fang, Min ^a   Zhu, Xiao Long ^a   Zhao, Yan Xin ^a   Liu, Xue Yuan ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA,GAMMA DIBROMOMETHYLENE 6 N,N DIETHYLADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; LEVODOPA; PHOSPHOPROTEIN; REACTIVE OXYGEN METABOLITE; APYRASE; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CELL VIABILITY ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; IMMUNOFLUORESCENCE; LDH ASSAY; MALE; MTT ASSAY; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PC12 CELL LINE; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BRAIN; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; METABOLISM; NERVE CELL; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, CD; APYRASE; BRAIN; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HYDROGEN PEROXIDE; LEVODOPA; MALE; NEURONS; OXIDATIVE STRESS; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

EID: 84899698654     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095387     Document Type: Article

References (69)

1. Hoyt KR, Reynolds IJ, Hastings TG (1997) Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp Neurol 143: 269-281.
2. Spencer JP, Jenner P, Halliwell B (1995) Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 6: 1480-1484.
3. Mena MA, Davila V, Sulzer D (1997) Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 69: 1398-1408.
4. Pardo B, Mena MA, Casarejos MJ, Paino CL, De Yebenes JG (1995) Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res 682: 133-143.
5. Langeveld CH, Jongenelen CA, Schepens E, Stoof JC, Bast A, et al. (1995) Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development. Neurosci Lett 192: 13-16.
6. Han SK, Mytilineou C, Cohen G (1996) L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 66: 501-510.
7. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, et al. (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19: 997-1005.
8. Shin JY, Park HJ, Ahn YH, Lee PH (2009) Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. J Neurochem 111: 1042-1050.
9. Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, et al. (2002) Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 109: 53-67.
10. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, et al. (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351: 2498-2508.
11. Holgado-Madruga M, Moscatello DK, Emlet DR, Dieterich R, Wong AJ (1997) Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. Proc Natl Acad Sci U S A 94: 12419-12424.
12. Montminy MR, Sevarino KA, Wagner JA, Mandel G, Goodman RH (1986) Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proc Natl Acad Sci U S A 83: 6682-6686.
13. Shao J, Evers BM, Sheng H (2004) Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem 279: 14287-14293.
14. Gee K, Angel JB, Mishra S, Blahoianu MA, Kumar A (2007) IL-10 regulation by HIV-Tat in primary human monocytic cells: involvement of calmodulin/ calmodulin-dependent protein kinase-activated p38 MAPK and Sp-1 and CREB-1 transcription factors. J Immunol 178: 798-807.
15. Wang H, Hu Y, Tsien JZ (2006) Molecular and systems mechanisms of memory consolidation and storage. Prog Neurobiol 79: 123-135.
16. Barco A, Alarcon JM, Kandel ER (2002) Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell 108: 689-703.
17. Hashimoto N, Matsumoto T, Mabe H, Hashitani T, Nishino H (1994) Dopamine has inhibitory and accelerating effects on ischemia-induced neuronal cell damage in the rat striatum. Brain Res Bull 33: 281-288.
18. Zimmermann H (1992) 59-Nucleotidase: molecular structure and functional aspects. Biochem J 285 (Pt 2): 345-365.
19. Montminy M (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66: 807-822.
20. Liao H, Hyman MC, Baek AE, Fukase K, Pinsky DJ (2010) cAMP/CREBmediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J Biol Chem 285: 14791-14805.
21. Maliszewski CR, Delespesse GJ, Schoenborn MA, Armitage RJ, Fanslow WC, et al. (1994) The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J Immunol 153: 3574-3583.
22. Mizumoto N, Kumamoto T, Robson SC, Sevigny J, Matsue H, et al. (2002) CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med 8: 358-365.
23. Langston HP, Ke Y, Gewirtz AT, Dombrowski KE, Kapp JA (2003) Secretion of IL-2 and IFN-gamma, but not IL-4, by antigen-specific T cells requires extracellular ATP. J Immunol 170: 2962-2970.
24. Dombrowski KE, Ke Y, Brewer KA, Kapp JA (1998) Ecto-ATPase: an activation marker necessary for effector cell function. Immunol Rev 161: 111-118.
25. Hyman MC, Petrovic-Djergovic D, Visovatti SH, Liao H, Yanamadala S, et al. (2009) Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 119: 1136-1149.
26. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, et al. (2003) Metabolic control of excessive extracellular nucleotide accumulation by CD39/ ecto-nucleotidase-1: implications for ischemic vascular diseases. J Pharmacol Exp Ther 305: 9-16.
27. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, et al. (2003) Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 1: 2497-2509.
28. Atkinson B, Dwyer K, Enjyoji K, Robson SC (2006) Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. Blood Cells Mol Dis 36: 217-222.
29. Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R (2006) Multiple cAMPinduced signaling cascades regulate prolactin expression in T cells. Cell Mol Life Sci 63: 92-99.
30. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, et al. (2007) CD39/ ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116: 1784-1794.
31. Marcus AJ, Broekman MJ, Drosopoulos JH, Pinsky DJ, Islam N, et al. (2001) Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases. Ital Heart J 2: 824-830.
32. Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, et al. (2002) Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 109: 1031-1040.
33. Marcus AJ, Broekman MJ, Drosopoulos JH, Olson KE, Islam N, et al. (2005) Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 31: 234-246.
34. Gerfen CR (2000) Dopamine-mediated gene regulation in models of Parkinson's disease. Ann Neurol 47: S42-50; discussion S50-42.
35. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, et al. (2002) Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61: 186-196.
36. Calon F, Hadj Tahar A, Blanchet PJ, Morissette M, Grondin R, et al. (2000) Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci 23: S92-100.
37. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
38. Jackson DM, Westlind-Danielsson A (1994) Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 64: 291-370.
39. Robinson SW, Caron MG (1997) Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol Pharmacol 52: 508-514.
40. Maudsley S, Martin B, Luttrell LM (2005) The origins of diversity and specificity in g protein-coupled receptor signaling. J Pharmacol Exp Ther 314: 485-494.
41. Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5: 173-183.
42. Zhen X, Uryu K, Wang HY, Friedman E (1998) D1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun aminoterminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. Mol Pharmacol 54: 453-458.
43. Rogue P, Malviya AN (1994) Regulation of signalling pathways to the nucleus by dopaminergic receptors. Cell Signal 6: 725-733.
44. Oh JD, Del Dotto P, Chase TN (1997) Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci Lett 228: 5-8.
45. Chase TN, Oh JD (2000) Striatal dopamine-and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23: S86-91.
46. Kim DS, Palmiter RD, Cummins A, Gerfen CR (2006) Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signalregulated kinase activity in dopamine-deficient mice. Neuroscience 137: 1381-1388.
47. Brown P, Gerfen CR (2006) Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway. J Comp Neurol 498: 415-430.
48. Papadeas ST, Blake BL, Knapp DJ, Breese GR (2004) Sustained extracellular signal-regulated kinase 1/2 phosphorylation in neonate 6- hydroxydopaminelesioned rats after repeated D1-dopamine receptor agonist administration: implications for NMDA receptor involvement. J Neurosci 24: 5863-5876.
49. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22: 5042-5054.
50. Zhao W, Huang Y, Liu Z, Cao BB, Peng YP, et al. (2013) Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway. PLoS One 8: e65860.
51. Carlezon WA Jr, Duman RS, Nestler EJ (2005) The many faces of CREB. Trends Neurosci 28: 436-445.
52. Dragunow M (2004) CREB and neurodegeneration. Front Biosci 9: 100-103.
53. Riccio A, Ginty DD (2002) What a privilege to reside at the synapse: NMDA receptor signaling to CREB. Nat Neurosci 5: 389-390.
54. Barth AL, McKenna M, Glazewski S, Hill P, Impey S, et al. (2000) Upregulation of cAMP response element-mediated gene expression during experiencedependent plasticity in adult neocortex. J Neurosci 20: 4206-4216.
55. Lonze BE, Ginty DD (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35: 605-623.
56. Impey S, Fong AL, Wang Y, Cardinaux JR, Fass DM, et al. (2002) Phosphorylation of CBP mediates transcriptional activation by neural activity and CaM kinase IV. Neuron 34: 235-244.
57. Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, et al. (2000) Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J Neurosci 20: 8443-8451.
58. Liu FC, Graybiel AM (1998) Dopamine and calcium signal interactions in the developing striatum: control by kinetics of CREB phosphorylation. Adv Pharmacol 42: 682-686.
59. Cavanaugh JE, Jaumotte JD, Lakoski JM, Zigmond MJ (2006) Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. J Neurosci Res 84: 1367-1375.
60. Oh JD, Chartisathian K, Ahmed SM, Chase TN (2003) Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopainduced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. J Neurosci Res 72: 768-780.
61. Viola H, Furman M, Izquierdo LA, Alonso M, Barros DM, et al. (2000) Phosphorylated cAMP response element-binding protein as a molecular marker of memory processing in rat hippocampus: effect of novelty. J Neurosci 20: RC112.
62. Silva AJ, Kogan JH, Frankland PW, Kida S (1998) CREB and memory. Annu Rev Neurosci 21: 127-148.
63. Pittenger C, Kandel E (1998) A genetic switch for long-term memory. C R Acad Sci III 321: 91-96.
64. Centonze D, Picconi B, Gubellini P, Bernardi G, Calabresi P (2001) Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur J Neurosci 13: 1071-1077.
65. Cenci MA, Tranberg A, Andersson M, Hilbertson A (1999) Changes in the regional and compartmental distribution of FosB-and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic Ldopa treatment. Neuroscience 94: 515-527.
66. Mabuchi T, Kitagawa K, Kuwabara K, Takasawa K, Ohtsuki T, et al. (2001) Phosphorylation of cAMP response element-binding protein in hippocampal neurons as a protective response after exposure to glutamate in vitro and ischemia in vivo. J Neurosci 21: 9204-9213.
67. Arnauld E, Arsaut J, Demotes-Mainard J (1998) Conditional coupling of striatal dopamine D1 receptor to transcription factors: ontogenic and regional differences in CREB activation. Brain Res Mol Brain Res 60: 127-132.
68. Liu FC, Graybiel AM (1998) Region-dependent dynamics of cAMP response element-binding protein phosphorylation in the basal ganglia. Proc Natl Acad Sci U S A 95: 4708-4713.
69. L' evesque SA, Lavoie E'G, Lecka J, Bigonnesse F & S' evigny J (2007)Specificity of the ecto-ATPase inhibitor ARL 67156 on humanand mouse ectonucleotidases. Brit J Pharmacol152: 141-150.